Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD19/anti-CD79b 4SCAR-expressing bispecific T cells

A preparation of T lymphocytes that are genetically engineered to express a fourth-generation chimeric antigen receptor (4SCAR) targeting the two tumor-associated antigens (TAAs) CD19 and B-cell antigen receptor complex-associated protein beta chain (CD79b; B-cell-specific glycoprotein B29), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/anti-CD79b 4SCAR-expressing bispecific T cells are directed to and induce selective toxicity in CD19- and CD79b-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD79b, a B-cell surface antigen and critical receptor for successful B-cell development, is part of the B-cell receptor (BCR) signaling complex. It is widely expressed in certain subtypes of B-cell lymphomas. CD19 and CD79b are expressed at high levels on tumor cells but not at significant levels on normal tissues. Targeting two antigens may protect against antigen escape and may enhance CAR-T cell efficacy.
Synonym:anti-CD19/anti-CD79b 4SCAR T cells
anti-CD19/CD79b bispecific 4SAR T cells
bi-4SCAR-CD19/79b T cells
bi-specific CD19/79b 4SCAR-T cells
CD19/79b bi-specific 4SCAR-T cells
Search NCI's Drug Dictionary